Results 21 to 30 of about 274,289 (156)
MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]
, 2020 Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang +22 more
core +1 more source
BMC Pulmonary Medicine, 2017 Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum +9 more
doaj +1 more source
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]
, 2013 BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group, +13 more
core +1 more source
Life, 2023 Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes ...
Georgios E. Papadopoulos +12 more
doaj +1 more source
Metformin reverses development of pulmonary hypertension via aromatase inhibition [PDF]
, 2016 Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear. The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP ...
Dean, Afshan +4 more
core +2 more sources
Macitentan in daily clinical practice: A single centre, 1-year experience
Pulmonology, 2018 The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events.
S. Cadenas-Menéndez +5 more
doaj +3 more sources
Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. [PDF]
, 2016 Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes
Ahmed, Mohamed +5 more
core +2 more sources
Pulmonary Circulation, 2019 A 36-year-old woman presented with recurrent pulmonary emboli (PE) despite oral anticoagulation. She was a type I diabetic with severe gastroparesis requiring insertion of multiple long-term peripherally inserted central catheters (PICC) over a 10-year ...
Abigail Masding +10 more
doaj +1 more source
Pulmonary hypertension associated with left-sided heart disease
Swiss Medical Weekly, 2017 Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease,
Micha T. Maeder +5 more
doaj +1 more source
Non-invasive assessment of pulmonary vascular resistance in pulmonary hypertension: Current knowledge and future direction [PDF]
, 2017 Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised. Pulmonary hypertension is not a diagnosis in itself; it is caused by a number of differing diseases each with different treatments and prognoses.
Hills, G +4 more
core +2 more sources